Clinical Trial Update: Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating a gamma-delta T cell product in combination with low-dose radiotherapy for locally advanced or metastatic non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Gamma-delta T cell product (gamma-delta T cells)

Snippet

Sponsor: Kiromic BioPharma Inc. | Conditions: Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors | Phase 1 | Status: RECRUITING